Loading...
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione, Sara Carlino, M Mangana, J Mooradian, M McArthur, G Schadendorf, D Hauschild, A Menzies, A Arance, A Ascierto, P
Valpione, Sara
Carlino, M
Mangana, J
Mooradian, M
McArthur, G
Schadendorf, D
Hauschild, A
Menzies, A
Arance, A
Ascierto, P
Citations
Altmetric:
Abstract
Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy.
Description
Date
2018-01-19
Publisher
Collections
Files
Keywords
Type
Article
Citation
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. 2018, 91:116-124 Eur J Cancer